氨磺必利与利培酮治疗首发精神分裂症疗效和安全性对比分析

王彦红

DOI：10.16662/j.cnki.1674-0742.2017.23.138

[摘要] 目的 研究氨磺必利与利培酮治疗首发精神分裂症患者的临床效果安全性。方法 方便选取该院2015年8月—2016年12月期间所收治的64例首发精神分裂症患者进行研究，对患者进行随机分组，研究组和对照组，每组32例，对照组应用利培酮治疗，研究组应用氨磺必利治疗，对比分析两组患者的治疗总有效率与不良反应发生情况（TESS评分），观察两组患者的阴性与阳性综合征量表评分与CDSS评分。结果 研究组治疗总有效率为84.38%，对照组治疗总有效率为81.25%，两组差异无统计学意义（P>0.05）。治疗后研究组患者PANSS阴性减分（8.24±5.15）分、CDSS评分（6.41±1.52）分与对照组[（5.62±4.13）分、（5.23±2.40）分]比較差异有统计学意义，且研究组患者的不良反应发生率（25.00%）显著低于对照组（53.13%），两组差异有统计学意义（P<0.05）。结论 在首发精神分裂症患者应用氨磺必利治疗的效果与利培酮相比，差异无统计学意义，但是若患者的临床症状属阴性症状，那么可以应用氨磺必利进行治疗，效果更为明显，且不良反应少，具有较高的安全性，值得推广应用。

[关键词] 氨磺必利；利培酮；首发精神分裂症；安全性

[中图分类号] R749 [文献标识码] A [文章编号] 1674-0742（2017）08（b）-0138-03

Comparative Analysis of the Efficacy and Safety of Amisulpride and Risperidone in the Treatment of First-episode Schizophrenia

WANG Yan-hong

Department of Psychiatry， Heze No.3 Peoples Hospital， Heze， Shandong Province， 274000 China

[Abstracts] Objective Objective This paper tries to study the clinical efficacy of amisulpride and risperidone in the treatment of first-episode schizophrenic patients. Methods 64 cases treated in this hospital during August 2015 to December 2016 were conveniently selected and randomly divided into the study group and the control group， with 32 cases in each group， the control group was treated with risperidone treatment， the study group was treated with amisulpride， the total effective rate of treatment and adverse reactions （TESS score） of the two groups were observed， and the negative and positive syndrome scale and CDSS score were observed. Results The total effective rate was 84.38% in the study group， the total effective rate in the control group was 81.25%， there was no significant difference between the two groups（P>0.05）； PANSS negative score of the study group after treatment was （8.24±5.15）points， CDSS subtraction was （6.41±1.52）points and that of the control group was（5.62±4.13）points， （5.23±2.40）points， the difference was significantly different， and the incidence of adverse reactions in the study group was 25.00%， significantly lower than in the control group of 53.13%， and the difference was statistically significant（P<0.05）. Conclusion There is no significant difference in the efficacy of amisulpride treatment in patients with first-episode schizophrenia compared with risperidone， but if the clinical symptoms of patients are negative， then the effect of amisulpride is more obvious， with fewer adverse reactions and high security， it is worth promotion and application.

[Key words] Amisulpride； Risperidone； First-episode schizophrenia； Safety

First-episode schizophrenia 是一种病因不明确的精神病，临床表现为症状各异的综合症状，一般情况下，患者意识不明确，智能基本正常，与正常人无异。最近几年，相关学者研究出了一种新型的抗精神病药物[1]，该药物不良反应较少，氨磺必利与利培酮都属于非典型康神经病药物，为研究两种药物的治疗效果。该文特此对该院在2015年8月—2016年12月期间所收治的64例首发精神分裂症患者进行探讨，现报道如下。……